Agreement On EU’s Radical Pharma Reform Plans ‘Could Take Three Years’
Executive Summary
The controversial nature of some of the plans in the EU medicines legislative overhaul suggests a long road ahead for negotiations at the European Parliament and Council, with some “substantial amendments” likely along the way.
You may also be interested in...
EU Pharma Revision: Legislators Prepare For Long-Haul Debate
The European Parliament and the Council of the EU are preparing their positions on the planned overhaul of the EU medicines legislation ahead of discussions that are expected to take two to three years.
EU Drug Approvals Could Be Denied If Environmental Risks Not Properly Assessed
As part of its revision of the EU medicines legislation, the European Commission is proposing tighter rules to reduce the environmental impact of medicines. Companies may want to start thinking now about whether their current environmental risk assessment processes would meet the likely new requirements.
EU Pharma Reform Proposes Cuts In Regulatory Protections & Faster Drug Approval Times
Proposals for the overhaul of the EU pharmaceutical legislation will make medicines more widely available, accessible and affordable while supporting innovation and boosting the “competitiveness and attractiveness” of Europe’s pharma industry, the European Commission claims. The research-based industry thinks otherwise, saying cuts in regulatory protections will undermine R&D.